Oligonucleotide Synthesis Market by Offerings (Synthesis products [Consumables, Equipment], Synthesized Oligos (Type [DNA, RNA], Oligo-based Drugs (Type [ASO, siRNA), Therapy Area [Rare Diseases, Neurology, Oncology], Competition - Global Forecast to 2031

Market Size
$14.64B
MARKET SIZE, 2026
Projected Market Size
$32.72B
MARKET SIZE, 2031
CAGR
17.4%
CAGR (2026-2031)
Forecast Period
2026-2031
FORECAST PERIOD

OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, SHARE & GROWTH SNAPSHOT

oligonucleotide-synthesis-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global oligonucleotide synthesis market is projected to grow from USD 14.64 billion in 2026 to USD 32.72 billion by 2031, at a CAGR of 17.4% during the forecast period. The market was valued at USD 11.66 billion in 2025. The major drivers of this market's growth include rapid clinical advances in RNA-based therapeutics, the widespread adoption of high-throughput CRISPR gene-editing screening libraries, the accelerating commercial scale-up of next-generation sequencing (NGS) diagnostics, and a significant influx of venture capital into disruptive enzymatic DNA synthesis platforms.

KEY TAKEAWAYS

  • MARKET SNAPSHOT:
    Base Year Market Size (2025): USD 11.66 Billion
    Current Market Size (2026): USD 14.64 Billion
    Forecast Market Size (2031): USD 32.72 Billion
    CAGR (2026–2031): 17.4%
  • SEGMENT LEADERSHIP:
    Regional Leader: North America dominated the global oligonucleotide synthesis market in 2025.
    Product Leader: Oligonucleotide-based drugs accounted for approximately 71.5% of the market in 2025.
    Type Leader: Reagents & consumables accounted for approximately 92.1% of the oligonucleotide synthesis products market in 2025.
    End User Leader: Specialty clinics accounted for approximately 44.7% of the market in 2025.
  • MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
    Leading companies in the oligonucleotide-based drugs market include Biogen, Alnylam Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Novartis AG, while key players in the oligonucleotide synthesis products market include Danaher Corporation, Thermo Fisher Scientific Inc., and Merck KGaA.
    Emerging companies such as Biolegio B.V. (Netherlands), Biolytic Lab Performance, Inc. (US), and Bio-Synthesis, Inc. (US) are rapidly expanding their presence by commercializing oligonucleotide synthesis products, synthesizers, and synthesized oligonucleotides.

The oligonucleotide synthesis market is growing steadily, driven by rising demand for therapeutic oligos (siRNA, ASO, mRNA adapters, CRISPR guides) and for clinical-grade GMP manufacturing. Growth is also fueled by routine use in qPCR/NGS library prep, companion diagnostics, and synthetic biology (gene circuits, DNA data storage, pooled screens). As programs advance from research to IND/BLA, buyers prioritize fast turnaround, high purity, and scalable QC (HPLC/UPLC, LC–MS).

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The fundamental shift from chemical small-molecules to advanced biotechnology therapies is significantly disrupting the oligonucleotide synthesis market. Over the forecast period from 2026 to 2031, traditional synthesis boundaries are increasingly dissolving as high-growth therapeutic areas—specifically oncology, precision neurology, and cardiovascular diseases—necessitate highly complex, long-chain oligonucleotides. This development is inducing substantial disruptions across related biological sectors: next-generation gene therapies are requiring custom-engineered single-guide RNAs, metagenomic sequencing is compelling the production of extensive parallel custom libraries, and mRNA-based therapeutic vaccines are scaling to commercial volumes. Consequently, synthesis providers must strategically transition from legacy laboratory-scale chemistries to high-throughput platforms capable of supporting these diverse macromolecular pipelines.

oligonucleotide-synthesis-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Increasing use of synthesized oligos in therapeutic & diagnostic applications
  • Growing government investments in life science research and synthetic biology
RESTRAINTS
Impact
Level
  • Complexities associated with therapeutic oligonucleotides
OPPORTUNITIES
Impact
Level
  • Increasing R&D investments by key players in emerging economies
CHALLENGES
Impact
Level
  • Lack of standard regulations
  • Delivery of oligonucleotide drugs to specific targets

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Increasing use of synthesized oligos in therapeutic & diagnostic applications

The primary driver of market expansion through 2031 is the accelerating therapeutic and diagnostic shift toward high-complexity nucleic acid modalities. The broadening clinical validation of oligonucleotide-based candidates for highly prevalent neurological conditions and orphan indications has spurred a wave of global regulatory approvals, anchoring long-term market confidence. This expanding commercial portfolio is further bolstered by an aggressive, multi-indication clinical pipeline advancing into personalized oncology and metabolic diseases. Furthermore, traditional diagnostic paradigms are being disrupted by the integration of ultra-pure, high-throughput oligonucleotides into next-generation molecular diagnostics, microarrays, and precision genetic testing platforms.

Restraint: Complexities associated with therapeutic oligonucleotides

The primary market restraint through 2031 is the high technical difficulty of ensuring sequence consistency and structural stability. As synthesis length increases to create more complex genetic therapies, it becomes harder to prevent length-related mutations and to handle large amounts of toxic waste during purification. This results in a higher environmental impact and greater material waste, leading to stricter regulations and sustainability concerns that increase production costs for custom sequences.

Opportunity: Increasing R&D investments by key players in emerging economies

Massive growth opportunities are emerging between 2026 and 2031, driven by substantial life science infrastructure spending across emerging economies, particularly in the Asia-Pacific and Latin America regions. Tier-1 players are leveraging these regions to build clinical networks and local bio-clusters, supported by expanding biotechnology frameworks and cost-effective manufacturing capabilities. Concurrently, the operational commercialization of enzyme-mediated synthesis platforms offers a lucrative avenue for rapid, reagent-free production of ultra-long DNA and RNA sequences.

Challenge: Lack of standard regulations and delivery of oligonucleotide drugs

The most significant operational challenge remains the severe bottleneck in intracellular targeted delivery and the fragmented international regulatory landscape. Oligonucleotide therapies face substantial physiological barriers, requiring highly advanced lipid nanoparticle (LNP) and GalNAc conjugation technologies to safely cross cell membranes without triggering adverse immune reactions. This biological targeting hurdle is further compounded by the complete absence of unified cross-border standards for clinical-grade nucleic acid therapeutic approvals.

OLIGONUCLEOTIDE SYNTHESIS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Deployed high-fidelity single-stranded custom oligonucleotide pools (oPools Oligo Pools) to build massive parallel sequence variations for cell line development and high-throughput CRISPR screening libraries Delivered industry-leading low error rates under 1 in 2,000 bases

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The oligonucleotide synthesis market operates within a highly interconnected, multi-tiered commercial value chain. The foundation comprises upstream instrumentation and reagent suppliers that provide the specialized chemistries and automated hardware required for strand assembly. In the midstream sector, pharmaceutical companies, biotechnology firms, and specialized CDMOs use these technologies to manufacture custom nucleic acid therapeutics, diagnostic arrays, and screening libraries. The downstream tier comprises hospitals, clinical research networks, and diagnostic laboratories that deploy these finished molecular tools in patient care. This entire ecosystem is governed by strict regulatory frameworks that mandate rigorous quality assurance, batch uniformity, and environmental compliance across all operational tiers.

oligonucleotide-synthesis-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

oligonucleotide-synthesis-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Oligonucleotide Synthesis Market, By Offering

In 2025, the oligonucleotide-based drugs segment maintained its dominant position as the largest and fastest-growing segment in the market. The primary factors driving this sustained expansion include an accelerating rate of global regulatory approvals for novel nucleic acid therapies and a surge in clinical research targeting rare diseases. Furthermore, the market is experiencing a significant strategic shift toward developing innovative oligonucleotide-based therapeutics for high-prevalence, common indications such as cardiovascular disorders, metabolic diseases, and oncology.

Oligonucleotide Synthesis Products Market, By Application

In 2025, the therapeutic applications segment held the largest share of the oligonucleotide synthesis products market, driven by expanding clinical and commercial pipelines for oligonucleotide medicines, which require scalable and GMP-compatible synthesis and purification technologies. Growth is also supported by the recurring consumption of phosphoramidites, solid supports, activators, solvents, purification columns, filters, and other materials in every therapeutic-oligo manufacturing batch.

Oligonucleotide -based drugs Market, By End User

In 2025, the specialty clinics segment maintained the largest share of the oligonucleotide-based drugs market, driven by the expansion of specialized in-house molecular pharmacy networks and advanced genetic treatment centers within major healthcare systems.

REGION

North America to be fastest-growing region in overall global oligonucleotide synthesis market during forecast period

The North American oligonucleotide synthesis market is maintaining a commanding compound annual growth rate (CAGR), primarily propelled by the expanding development of oligo-based pharmaceuticals, an assertive wave of domestic mergers and acquisitions, and multi-million dollar capacity expansions within Contract Development and Manufacturing Organizations (CDMOs). Instead of solely depending on basic research grants, regional growth is driven by the swift advancement of antisense oligonucleotides and personalized messenger RNA (mRNA) candidates into late-stage clinical pipelines. This clinical progression is significantly supported by a well-established, high-density infrastructure comprising premier biopharmaceutical manufacturing hubs and a mature venture capital ecosystem that facilitates the rapid scaling of early-stage genomic platforms.

oligonucleotide-synthesis-market Region

OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX

Within the current market framework, Danaher Corporation continues to anchor its position as the clear market leader, leveraging its extensive DNA/RNA portfolio—spanning rapid research-grade synthesis to high-volume cGMP supplies—to achieve unparalleled global scale. By deeply integrating its custom synthesis pipelines with corporate bioprocess automation and analytical instruments, the company delivers superior quality and rapid turnaround across diagnostics, therapeutics, and synthetic biology. Meanwhile, Maravai LifeSciences operates as a dynamic emerging leader, rapidly expanding its specialized cGMP oligo capacity and modified-nucleotide production footprint. Backed by its high-demand CleanCap mRNA capping technology and end-to-end CDMO services, Maravai remains uniquely positioned to capture late-stage clinical pipelines and advance directly into the market's leading quadrant.

oligonucleotide-synthesis-market Evaluation Metrics oligonucleotide-synthesis-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 11.66 billion
Market Size in 2026 (Value) USD 14.64 billion
Market Forecast in 2031 (Value) USD 32.72 billion
Growth Rate CAGR of 17.40% from 2026-2031
Years Considered 2024-2031
Base Year 2025
Forecast Period 2026-2031
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Offering:
    • Oligonucleotide-based drugs
    • Synthesized Oligonucleotides
    • Oligonucleotide Synthesis Products
  • Oligonucleotide-based Drugs:
    • By Type (Antisense Oligonucleotide-based Drugs
    • siRNA Oligonucleotide-based Drugs
    • Other Oligonucleotide-based Drugs
  • By Therapeutic Area:
    • Rare Diseases
    • Cardiometabolic Diseases
    • Neurology
    • Other Therapeutic Areas
  • By End User:
    • Hospitals
    • Specialty Clinics
    • Home Care Settings
    • Other End Users); Synthesized Oligonucleotides
  • By Type:
    • Predesigned Oligonucleotides
    • Custom Oligonucleotides
  • By Application:
    • Therapeutic Development
    • Research Applications (PCR
    • Sequencing
    • Others)
    • Diagnostic Applications
  • By End User:
    • Pharmaceutical & Biotechnology Companies
    • CROs & CDMOs
    • Diagnostic Companies & Laboratories
    • Academic & Research Institutes; Oligonucleotide Synthesis Products
    • By Type
  • By Application:
    • Therapeutic Applications
    • Research Applications
    • Diagnostic Applications
  • By End User:
    • Biopharmaceutical & Biotechnology Companies
    • CROs & CDMOs
    • Academic & Research Institutes
    • Diagnostic Companies & Laboratories
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa

WHAT IS IN IT FOR YOU: OLIGONUCLEOTIDE SYNTHESIS MARKET REPORT CONTENT GUIDE

oligonucleotide-synthesis-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
CDMO Vendor Evaluation & Selection Matrix Systematic scoring of primary contract manufacturing providers based on active cGMP facility cleanrooms, regulatory compliance histories, and batch purification capacity Accelerates the clinical outsourcing process while minimizing batch-to-batch consistency risks in volatile supply chains

RECENT DEVELOPMENTS

  • December 2025 : EnPlusOne Biosciences commercialized its proprietary enzymatic RNA synthesis platform, offering an alternative to traditional chemistry and enabling the reagent-free production of longer, modified RNA strands without legacy capping constraints.
  • February 2025 : Astellas Pharma Inc. (Japan) announced that the US FDA approved expanded US Prescribing information for IZERVAY for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a result, IZERVAY was approved without a duration limit for dosing.
  • September 2025 : WuXi STA officially opened its expanded large-scale oligonucleotide and peptide manufacturing facility, significantly ramping up midstream cGMP capacity to meet a surging pipeline of global commercial-phase antisense and siRNA drug contracts.

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
63
2
EXECUTIVE SUMMARY
 
 
 
 
 
70
3
PREMIUM INSIGHTS
 
 
 
 
 
78
4
MARKET OVERVIEW
Oligonucleotide therapeutics surge with regulatory approvals, RNA pipeline growth, and strategic industry investments.
 
 
 
 
 
82
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
RISING COMMERCIALIZATION AND REGULATORY APPROVALS OF OLIGONUCLEOTIDE THERAPEUTICS
 
 
 
 
 
 
4.2.1.2
EXPANDING RNA THERAPEUTICS PIPELINE AND ADOPTION OF CHEMICALLY MODIFIED OLIGOS
 
 
 
 
 
 
4.2.1.3
GROWING USE OF PCR, QPCR, NGS, CRISPR, SYNTHETIC BIOLOGY, AND MOLECULAR DIAGNOSTICS
 
 
 
 
 
 
4.2.1.4
INCREASING OUTSOURCING OF OLIGONUCLEOTIDE SYNTHESIS AND GMP MANUFACTURING TO CROS/CDMOS
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
COMPLEXITY OF LARGE-SCALE OLIGONUCLEOTIDE MANUFACTURING AND ANALYTICAL CONTROL
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
INCREASING GOVERNMENT AND INDUSTRY INVESTMENTS IN LIFE SCIENCES, RNA THERAPEUTICS, AND MANUFACTURING INFRASTRUCTURE
 
 
 
 
 
 
4.2.3.2
EXPANSION OF OLIGONUCLEOTIDE THERAPEUTICS INTO CARDIOMETABOLIC AND COMMON CHRONIC DISEASES
 
 
 
 
 
 
4.2.3.3
GROWTH OF COMPANION DIAGNOSTICS AND PRECISION MEDICINE
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
LACK OF STANDARD REGULATIONS
 
 
 
 
 
 
4.2.4.2
DELIVERY OF OLIGONUCLEOTIDE DRUGS TO SPECIFIC TARGETS
 
 
 
 
 
 
4.2.4.3
SUSTAINABILITY & WASTE MANAGEMENT IN PHOSPHORAMIDITE-BASED SYNTHESIS
 
 
 
 
4.3
UNMET NEEDS & WHITE SPACES
 
 
 
 
 
 
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
 
 
 
 
 
 
 
4.5.1
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN THE OLIGONUCLEOTIDE-BASED DRUGS MARKET
 
 
 
 
 
 
4.5.2
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET
 
 
 
 
5
INDUSTRY TRENDS
Discover how competitive forces and economic shifts reshape the oligonucleotide synthesis market landscape.
 
 
 
 
 
93
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
OLIGONUCLEOTIDE-BASED DRUGS
 
 
 
 
 
 
 
5.1.1.1
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.1.2
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.1.3
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.1.4
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
 
SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE
 
 
 
 
 
 
 
5.1.2.1
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.2.2
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.2.3
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.2.4
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.2.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
5.2
MACROECONOMIC OUTLOOK
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS & FORECAST
 
 
 
 
 
 
5.2.3
TRENDS IN GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET
 
 
 
 
 
5.3
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
5.4
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.5
PRICING ANALYSIS
 
 
 
 
 
 
 
 
 
AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY KEY PLAYER,
 
 
 
 
 
 
5.5.2
AVERAGE SELLING PRICE OF EQUIPMENT, BY REGION, 2025
 
 
 
 
 
5.6
KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
5.8
INVESTMENT & FUNDING ACTIVITY
 
 
 
 
 
 
5.9
IMPACT OF 2025 US TARIFFS ON OLIGONUCLEOTIDE SYNTHESIS MARKET
 
 
 
 
 
 
 
 
5.9.1
INTRODUCTION
 
 
 
 
 
 
5.9.2
KEY TARIFF RATES
 
 
 
 
 
 
5.9.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.9.4
IMPACT ON COUNTRY/REGION
 
 
 
 
 
 
 
5.9.4.1
NORTH AMERICA
 
 
 
 
 
 
5.9.4.2
EUROPE
 
 
 
 
 
 
5.9.4.3
ASIA PACIFIC
 
 
 
 
 
5.9.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
 
 
5.9.5.1
HOSPITALS
 
 
 
 
 
 
5.9.5.2
SPECIALTY CLINICS
 
 
 
 
 
 
5.9.5.3
HOME CARE SETTINGS & OTHER END USERS
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations redefine oligonucleotide synthesis with groundbreaking patents and future-ready applications.
 
 
 
 
 
113
 
6.1
TECHNOLOGY ANALYSIS
 
 
 
 
 
 
 
6.1.1
KEY TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1.1
SOLID-PHASE PHOSPHORAMIDITE SYNTHESIS AND SCALE-UP
 
 
 
 
 
 
6.1.1.2
LIQUID-PHASE SYNTHESIS
 
 
 
 
 
 
6.1.1.3
CHEMICAL MODIFICATION & BACKBONE ENGINEERING
 
 
 
 
 
 
6.1.1.4
CONJUGATION & TARGETED DELIVERY CHEMISTRY
 
 
 
 
 
 
6.1.1.5
ENZYMATIC & NOVEL SYNTHESIS TECHNOLOGIES
 
 
 
 
 
 
6.1.1.6
HIGH-THROUGHPUT AUTOMATED OLIGONUCLEOTIDE SYNTHESIS
 
 
 
 
 
 
6.1.1.7
PURIFICATION & ANALYTICAL CHARACTERIZATION
 
 
 
 
 
6.1.2
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
6.1.2.1
MOLECULAR BIOLOGY & GENOMIC TECHNOLOGIES
 
 
 
 
 
 
6.1.2.2
SYNTHETIC BIOLOGY & GENE SYNTHESIS
 
 
 
 
 
6.1.3
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.1.3.1
ADVANCED OLIGONUCLEOTIDE DELIVERY TECHNOLOGIES
 
 
 
 
 
 
6.1.3.2
AI-ASSISTED OLIGONUCLEOTIDE DESIGN
 
 
 
 
6.2
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
6.3
FUTURE APPLICATIONS
 
 
 
 
 
 
6.4
IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
 
 
 
 
 
 
 
 
6.4.1
TOP USE CASES & MARKET POTENTIAL
 
 
 
 
 
 
6.4.2
INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
 
 
 
 
 
 
6.4.3
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN OLIGONUCLEOTIDE SYNTHESIS MARKET
 
 
 
 
 
6.5
PATENT ANALYSIS & INNOVATIONS
 
 
 
 
 
 
 
 
6.5.1
OLIGONUCLEOTIDE SYNTHESIS MARKET: PATENT ANALYSIS, 2015–2025
 
 
 
 
 
 
6.5.2
KEY INNOVATIONS
 
 
 
 
7
SUSTAINABILITY & REGULATORY LANDSCAPE
Navigate complex global regulations and sustainability standards to optimize compliance and market access.
 
 
 
 
 
123
 
7.1
REGIONAL REGULATIONS & COMPLIANCE
 
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
7.1.2
REGULATORY FRAMEWORK & REIMBURSEMENT
 
 
 
 
 
 
 
7.1.2.1
NORTH AMERICA
 
 
 
 
 
 
7.1.2.2
EUROPE
 
 
 
 
 
 
7.1.2.3
ASIA PACIFIC
 
 
 
 
 
 
7.1.2.4
REST OF THE WORLD
 
 
 
 
 
7.1.3
INDUSTRY STANDARDS
 
 
 
 
 
7.2
REIMBURSEMENT SCENARIO
 
 
 
 
 
 
7.3
SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
 
 
 
 
 
 
7.4
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
 
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock hidden buyer motivations and decision dynamics to enhance market profitability and overcome adoption barriers.
 
 
 
 
 
132
 
8.1
DECISION-MAKING PROCESS
 
 
 
 
 
 
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
 
 
 
 
 
 
 
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
8.2.2
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
8.4
UNMET NEEDS FROM END USERS
 
 
 
 
 
 
8.5
MARKET PROFITABILITY
 
 
 
 
 
9
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 23 Data Tables
 
 
 
 
 
136
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
OLIGONUCLEOTIDE-BASED DRUGS
 
 
 
 
 
 
 
9.2.1
RECURRING CONSUMABLES DEMAND, AUTOMATION UPGRADES, AND ADVANCED SCREENING PLATFORMS TO DRIVE GROWTH
 
 
 
 
 
9.3
SYNTHESIZED OLIGONUCLEOTIDES
 
 
 
 
 
 
 
9.3.1
GROWING ADOPTION OF PCR, QPCR, NGS, AND CRISPR-BASED GENOME EDITING TO GENERATE SUBSTANTIAL DEMAND FOR CUSTOM PRIMERS
 
 
 
 
 
9.4
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
 
 
 
 
 
 
 
9.4.1
INCREASING INSTALLATION OF AUTOMATED OLIGONUCLEOTIDE SYNTHESIZERS TO SUPPORT MARKET GROWTH
 
 
 
 
10
OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 25 Data Tables
 
 
 
 
 
149
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS
 
 
 
 
 
 
 
 
ASO-BASED DRUGS ACCOUNTED FOR LARGEST MARKET SHARE DUE TO THEIR ESTABLISHED CLINICAL SUCCESS ACROSS RARE AND
 
 
 
 
 
10.3
SIRNA OLIGONUCLEOTIDE-BASED DRUGS
 
 
 
 
 
 
 
10.3.1
EXPANDING COMMERCIAL ADOPTION AND STRONG LATE-STAGE PIPELINES TO DRIVE GROWTH
 
 
 
 
 
10.4
OTHER OLIGONUCLEOTIDE-BASED DRUGS
 
 
 
 
 
11
OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 26 Data Tables
 
 
 
 
 
164
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
RARE DISEASES
 
 
 
 
 
 
 
11.2.1
GROWING APPROVALS FOR ORPHAN DISEASES TO MAKE RARE DISEASES LARGEST THERAPEUTIC AREA FOR OLIGONUCLEOTIDE THERAPEUTICS
 
 
 
 
 
11.3
NEUROLOGICAL DISORDERS
 
 
 
 
 
 
 
11.3.1
COMMERCIAL SUCCESS OF RNA-TARGETED THERAPIES TO CONTINUE TO STRENGTHEN NEUROLOGY SEGMENT
 
 
 
 
 
11.4
CARDIOMETABOLIC DISEASES
 
 
 
 
 
 
 
11.4.1
EXPANDING RNA THERAPEUTICS FOR CARDIOVASCULAR DISEASES TO MAKE CARDIOMETABOLIC DISEASES FASTEST-GROWING THERAPEUTIC AREA
 
 
 
 
 
11.5
OTHER THERAPEUTIC AREAS
 
 
 
 
 
12
OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 29 Data Tables
 
 
 
 
 
180
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
SPECIALTY CLINICS
 
 
 
 
 
 
 
12.2.1
GROWING NETWORK OF SPECIALIZED RARE DISEASE TREATMENT CENTERS TO MAINTAIN SPECIALTY CLINICS AS LARGEST END-USER SEGMENT
 
 
 
 
 
12.3
HOSPITALS
 
 
 
 
 
 
 
12.3.1
COMPLEX PATIENT MANAGEMENT AND ADMINISTRATION OF ADVANCED OLIGONUCLEOTIDE THERAPIES TO CONTINUE TO SUPPORT HOSPITAL DEMAND
 
 
 
 
 
12.4
HOME CARE SETTINGS
 
 
 
 
 
 
 
12.4.1
SHIFT TOWARD CONVENIENT DOSING AND SELF-ADMINISTRATION TO MAKE HOME CARE SETTINGS FASTEST-GROWING END-USER SEGMENT
 
 
 
 
 
12.5
OTHER END USERS
 
 
 
 
 
13
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 36 Data Tables
 
 
 
 
 
198
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
PRIMERS
 
 
 
 
 
 
 
13.2.1
WIDESPREAD USE OF PRIMERS ACROSS RESEARCH, DIAGNOSTICS, AND THERAPEUTIC DEVELOPMENT TO FUEL GROWTH
 
 
 
 
 
13.3
PROBES
 
 
 
 
 
 
 
13.3.1
EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO DRIVE STRONG DEMAND FOR PROBES
 
 
 
 
 
13.4
DNA OLIGONUCLEOTIDES
 
 
 
 
 
 
 
13.4.1
BROAD APPLICABILITY ACROSS LIFE SCIENCE RESEARCH AND DIAGNOSTICS TO DRIVE SIGNIFICANT MARKET SHARE FOR DNA OLIGOS
 
 
 
 
 
13.5
RNA OLIGONUCLEOTIDES
 
 
 
 
 
 
 
13.5.1
RAPID GROWTH OF RNA THERAPEUTICS AND GENE-EDITING TECHNOLOGIES TO DRIVE MARKET MOMENTUM FOR RNA OLIGOS
 
 
 
 
 
13.6
OTHER OLIGONUCLEOTIDES
 
 
 
 
 
14
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 15 Data Tables
 
 
 
 
 
217
 
14.1
INTRODUCTION
 
 
 
 
 
 
14.2
CUSTOM OLIGONUCLEOTIDES
 
 
 
 
 
 
 
14.2.1
RAPID CLINICAL AND COMMERCIAL EXPANSION OF CHEMICALLY MODIFIED ANTISENSE AND SIRNA THERAPEUTICS TO MAKE CUSTOM OLIGONUCLEOTIDES FASTEST-GROWING SEGMENT
 
 
 
 
 
14.3
PREDESIGNED OLIGONUCLEOTIDES
 
 
 
 
 
 
 
14.3.1
PREDESIGNED OLIGONUCLEOTIDES CONTINUE TO WITNESS STEADY DEMAND OWING TO WIDESPREAD USE IN ROUTINE RESEARCH AND MOLECULAR DIAGNOSTICS
 
 
 
 
15
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 44 Data Tables
 
 
 
 
 
226
 
15.1
INTRODUCTION
 
 
 
 
 
 
15.2
RESEARCH APPLICATIONS
 
 
 
 
 
 
 
15.2.1
PCR
 
 
 
 
 
 
 
15.2.1.1
WIDESPREAD ADOPTION OF PCR ACROSS LIFE SCIENCE RESEARCH TO DRIVE MARKET GROWTH
 
 
 
 
 
15.2.2
NGS
 
 
 
 
 
 
 
15.2.2.1
SEQUENCING TO CONTINUE TO EXPAND WITH INCREASING ADOPTION OF NEXT-GENERATION SEQUENCING TECHNOLOGIES
 
 
 
 
 
15.2.3
OTHER RESEARCH APPLICATIONS
 
 
 
 
 
15.3
THERAEPUTIC DEVELOPMENT
 
 
 
 
 
 
 
15.3.1
EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO SUPPORT GROWTH OF MARKET FOR THERAPEUTIC DEVELOPMENT APPLICATIONS
 
 
 
 
 
15.4
DIAGNOSTIC APPLICATIONS
 
 
 
 
 
 
 
15.4.1
INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO EXPAND MARKET FOR DIAGNOSTIC APPLICATIONS
 
 
 
 
16
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 29 Data Tables
 
 
 
 
 
248
 
16.1
INTRODUCTION
 
 
 
 
 
 
16.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
16.2.1
EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO MAKE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES LARGEST END-USER SEGMENT
 
 
 
 
 
16.3
CROS & CDMOS
 
 
 
 
 
 
 
16.3.1
INCREASING OUTSOURCING OF OLIGONUCLEOTIDE DRUG DEVELOPMENT TO DRIVE FASTEST GROWTH AMONG CROS & CDMOS
 
 
 
 
 
16.4
DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES
 
 
 
 
 
 
 
16.4.1
GROWING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO DRIVE DEMAND
 
 
 
 
 
16.5
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
 
16.5.1
EXPANDING GENOMICS AND LIFE SCIENCE RESEARCH TO SUSTAIN DEMAND FROM ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
17
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 95 Data Tables
 
 
 
 
 
264
 
17.1
INTRODUCTION
 
 
 
 
 
 
17.2
OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES
 
 
 
 
 
 
 
17.2.1
OLIGONUCLEOTIDE SYNTHESIS REAGENTS
 
 
 
 
 
 
 
17.2.1.1
PHOSPHORAMIDITE BUILDING BLOCKS
 
 
 
 
 
 
 
 
17.2.1.1.1
DNA PHOSPHORAMIDITES
 
 
 
 
 
 
17.2.1.1.2
RNA PHOSPHORAMIDITES
 
 
 
 
 
 
17.2.1.1.3
MODIFIED PHOSPHORAMIDITES
 
 
 
 
17.2.1.2
ACTIVATORS/COUPLING REAGENTS
 
 
 
 
 
 
 
 
17.2.1.2.1
MIGRATION FROM STANDARD TETRAZOLE TO ETT- AND BTT-BASED ACTIVATORS TO RAISE COUPLING EFFICIENCY IN GMP-SCALE RNA AND MODIFIED-OLIGO SYNTHESIS
 
 
 
 
17.2.1.3
DEPROTECTION REAGENTS
 
 
 
 
 
 
 
 
17.2.1.3.1
RISING SYNTHESIS THROUGHPUT AND DEMAND FOR MILDER, MODIFICATION-COMPATIBLE DEPROTECTION CHEMISTRIES TO SUSTAIN DETRITYLATION REAGENT CONSUMPTION
 
 
 
 
17.2.1.4
CAPPING REAGENTS
 
 
 
 
 
 
 
 
17.2.1.4.1
TIGHTENING N-1 IMPURITY SPECIFICATIONS FOR THERAPEUTIC OLIGONUCLEOTIDES TO LIFT DEMAND FOR VALIDATED, HIGH-PURITY CAPPING REAGENT LOTS
 
 
 
 
17.2.1.5
OTHER REAGENTS
 
 
 
 
 
17.2.2
SOLID SUPPORTS
 
 
 
 
 
 
 
17.2.2.1
SHIFT TOWARD HIGH-LOADING CO-POLYMER CPG AND SINGLE-USE SYNTHESIS CASSETTES TO SUPPORT LONG-CHAIN, GMP-SCALE OLIGONUCLEOTIDE PRODUCTION
 
 
 
 
 
17.2.3
OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES
 
 
 
 
 
 
 
17.2.3.1
TIGHTENING GMP PURITY SPECIFICATIONS FOR THERAPEUTIC OLIGONUCLEOTIDES TO DRIVE DEMAND FOR PURIFICATION AND QC CONSUMABLES
 
 
 
 
17.3
OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT
 
 
 
 
 
 
 
17.3.1
ADOPTION OF FLOW-THROUGH, GMP-COMPLIANT SYNTHESIS PLATFORMS TO SCALE OLIGONUCLEOTIDE MANUFACTURING FROM RESEARCH THROUGH COMMERCIAL PRODUCTION
 
 
 
 
18
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
 
 
 
 
 
313
 
18.1
INTRODUCTION
 
 
 
 
 
 
18.2
RESEARCH APPLICATIONS
 
 
 
 
 
 
 
18.2.1
HIGH-VOLUME CONSUMPTION OF SYNTHESIS PRODUCTS ACROSS GENOMICS AND MOLECULAR BIOLOGY RESEARCH TO DRIVE GROWTH
 
 
 
 
 
18.3
THERAPEUTIC DEVELOPMENT
 
 
 
 
 
 
 
18.3.1
EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO BOOST MARKET
 
 
 
 
 
18.4
DIAGNOSTIC APPLICATIONS
 
 
 
 
 
 
 
18.4.1
DIAGNOSTICS APPLICATIONS TO CONTINUE TO EXPAND WITH INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE
 
 
 
 
19
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 29 Data Tables
 
 
 
 
 
325
 
19.1
INTRODUCTION
 
 
 
 
 
 
19.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
19.2.1
INCREASING INVESTMENTS IN OLIGONUCLEOTIDE DRUG DEVELOPMENT AND MANUFACTURING TO SUPPORT MARKET GROWTH
 
 
 
 
 
19.3
CROS & CDMOS
 
 
 
 
 
 
 
19.3.1
INCREASING OUTSOURCING OF OLIGONUCLEOTIDE MANUFACTURING TO DRIVE MARKET GROWTH
 
 
 
 
 
19.4
DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES
 
 
 
 
 
 
 
19.4.1
EXPANDED USE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS WITH GROWTH OF MOLECULAR DIAGNOSTICS TO BOOST DEMAND
 
 
 
 
 
19.5
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
 
19.5.1
ACADEMICS & RESEARCH INSTITUTES TO CONTINUE TO PROVIDE STABLE DEMAND DRIVEN BY EXPANDING GENOMICS AND LIFE SCIENCE RESEARCH
 
 
 
 
20
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 17 Countries | 442 Data Tables.
 
 
 
 
 
341
 
20.1
INTRODUCTION
 
 
 
 
 
 
20.2
NORTH AMERICA
 
 
 
 
 
 
 
20.2.1
US
 
 
 
 
 
 
 
20.2.1.1
MATURE ECOSYSTEM ACROSS OLIGO-BASED THERAPEUTICS, SYNTHESIZED OLIGONUCLEOTIDES, AND OLIGONUCLEOTIDE SYNTHESIS PRODUCTS TO DRIVE MARKET GROWTH
 
 
 
 
 
20.2.2
CANADA
 
 
 
 
 
 
 
20.2.2.1
STRONG ACADEMIC RESEARCH ECOSYSTEM TO SUPPORT MARKET GROWTH
 
 
 
 
20.3
EUROPE
 
 
 
 
 
 
 
20.3.1
GERMANY
 
 
 
 
 
 
 
 
ESTABLISHED CAPABILITIES FOR DEVELOPMENT AND MANUFACTURING OF
 
 
 
 
 
20.3.2
UK
 
 
 
 
 
 
 
20.3.2.1
ESTABLISHED NATIONAL PROGRAMS TO ENCOURAGE UTILIZATION OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
 
 
 
 
 
20.3.3
FRANCE
 
 
 
 
 
 
 
20.3.3.1
INCREASE IN RNA-RELATED RESEARCH BY BIOTECHNOLOGY COMPANIES AND ACADEMIC INSTITUTIONS TO DRIVE MARKET GROWTH
 
 
 
 
 
20.3.4
ITALY
 
 
 
 
 
 
 
20.3.4.1
HIGH DEMAND FOR MOLECULAR DIAGNOSTICS TO FAVOR ADOPTION OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
 
 
 
 
 
20.3.5
SPAIN
 
 
 
 
 
 
 
20.3.5.1
GOVERNMENT ORGANIZATIONS INVESTING IN OLIGONUCLEOTIDE-RELATED RESEARCH ACTIVITIES TO DRIVE MARKET GROWTH
 
 
 
 
 
20.3.6
REST OF EUROPE
 
 
 
 
 
20.4
ASIA PACIFIC
 
 
 
 
 
 
 
20.4.1
JAPAN
 
 
 
 
 
 
 
20.4.1.1
EXPANDING COLLABORATION BETWEEN PHARMA COMPANIES AND ACADEMIC INSTITUTIONS FOR DEVELOPMENT OF OLIGONUCLEOTIDE THERAPEUTICS TO DRIVE MARKET GROWTH
 
 
 
 
 
20.4.2
CHINA
 
 
 
 
 
 
 
20.4.2.1
ROBUST NETWORK OF DOMESTIC COMPANIES OFFERING OLIGONUCLEOTIDE PRODUCTS TO SUPPORT MARKET GROWTH
 
 
 
 
 
20.4.3
INDIA
 
 
 
 
 
 
 
20.4.3.1
EXPANDING PRESENCE OF DOMESTIC SERVICE PROVIDERS TO OFFER HIGH-QUALITY DNA AND RNA OLIGONUCLEOTIDES FOR RESEARCH AND DIAGNOSTICS
 
 
 
 
 
20.4.4
SOUTH KOREA
 
 
 
 
 
 
 
20.4.4.1
HIGH DEMAND FOR CUSTOM OLIGONUCLEOTIDE SYNTHESIS SERVICES TO SUPPORT MARKET GROWTH
 
 
 
 
 
20.4.5
AUSTRALIA
 
 
 
 
 
 
 
20.4.5.1
WELL-ESTABLISHED BIOMEDICAL RESEARCH SECTOR TO FAVOR UTILIZATION OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
 
 
 
 
 
20.4.6
REST OF ASIA PACIFIC
 
 
 
 
 
20.5
LATIN AMERICA
 
 
 
 
 
 
 
20.5.1
BRAZIL
 
 
 
 
 
 
 
20.5.1.1
GOVERNMENT INITIATIVES AIMED AT STRENGTHENING GENOMIC SURVEILLANCE TO OFFER MARKET EXPANSION OPPORTUNITIES
 
 
 
 
 
20.5.2
MEXICO
 
 
 
 
 
 
 
20.5.2.1
GROWING NETWORK OF PHARMACEUTICAL MANUFACTURERS AND DIAGNOSTIC LABORATORIES TO OFFER MARKET EXPANSION OPPORTUNITIES
 
 
 
 
 
20.5.3
ARGENTINA
 
 
 
 
 
 
 
20.5.3.1
INCREASING INVESTMENT BY ACADEMIC INSTITUTIONS IN OLIGONUCLEOTIDE-BASED RESEARCH TO OFFER MARKET EXPANSION OPPORTUNITIES
 
 
 
 
 
20.5.4
REST OF LATIN AMERICA
 
 
 
 
 
20.6
MIDDLE EAST
 
 
 
 
 
 
 
20.6.1
GCC COUNTRIES
 
 
 
 
 
 
 
20.6.1.1
SAUDI ARABIA
 
 
 
 
 
 
 
 
20.6.1.1.1
NATIONAL GENOMICS INITIATIVES TO ENCOURAGE ADOPTION OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
 
 
 
 
20.6.1.2
UAE
 
 
 
 
 
 
 
 
20.6.1.2.1
GOVERNMENT-DRIVEN INITIATIVES AND SUBSTANTIAL INVESTMENTS TO IMPROVE UAE'S CAPABILITIES IN LIFE SCIENCE INDUSTRY
 
 
 
 
20.6.1.3
REST OF GCC COUNTRIES
 
 
 
 
 
20.6.2
REST OF MIDDLE EAST
 
 
 
 
 
20.7
AFRICA
 
 
 
 
 
 
 
20.7.1
GROWING INVESTMENTS IN PUBLIC HEALTH DIAGNOSTICS AND GENOMIC SURVEILLANCE ACTIVITIES TO DRIVE MARKET GROWTH
 
 
 
 
21
COMPETITIVE LANDSCAPE
Uncover strategic moves and market dominance of key players in oligonucleotide sectors.
 
 
 
 
 
567
 
21.1
INTRODUCTION
 
 
 
 
 
 
21.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
 
 
 
21.2.1
KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2023–2026
 
 
 
 
 
 
21.2.2
KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2023–2026
 
 
 
 
 
21.3
REVENUE ANALYSIS, 2021–2025
 
 
 
 
 
 
 
 
 
REVENUE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET,
 
 
 
 
 
 
21.3.2
REVENUE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2021–2025
 
 
 
 
 
21.4
MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
 
 
21.4.1
MARKET SHARE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2025
 
 
 
 
 
 
21.4.2
MARKET SHARE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2025
 
 
 
 
 
21.5
COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE-BASED DRUGS MARKET), 2025
 
 
 
 
 
 
 
 
21.5.1
STARS
 
 
 
 
 
 
21.5.2
EMERGING LEADERS
 
 
 
 
 
 
21.5.3
PERVASIVE PLAYERS
 
 
 
 
 
 
21.5.4
PARTICIPANTS
 
 
 
 
 
 
21.5.5
COMPANY FOOTPRINT: OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2025
 
 
 
 
 
 
 
21.5.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
21.5.5.2
REGION FOOTPRINT
 
 
 
 
 
 
21.5.5.3
DRUG TYPE FOOTPRINT
 
 
 
 
 
 
21.5.5.4
THERAPEUTIC AREA FOOTPRINT
 
 
 
 
21.6
COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET), 2025
 
 
 
 
 
 
 
 
21.6.1
STARS
 
 
 
 
 
 
21.6.2
EMERGING LEADERS
 
 
 
 
 
 
21.6.3
PERVASIVE PLAYERS
 
 
 
 
 
 
21.6.4
PARTICIPANTS
 
 
 
 
 
 
21.6.5
COMPANY FOOTPRINT: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2025
 
 
 
 
 
 
 
21.6.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
21.6.5.2
REGION FOOTPRINT
 
 
 
 
 
 
21.6.5.3
PRODUCT TYPE FOOTPRINT
 
 
 
 
21.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 
 
 
 
 
 
 
 
21.7.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
21.7.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
21.7.3
DYNAMIC COMPANIES
 
 
 
 
 
 
21.7.4
STARTING BLOCKS
 
 
 
 
 
 
21.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
21.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
21.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
21.8
BRAND/PRODUCT COMPARATIVE ANALYSIS
 
 
 
 
 
 
21.9
COMPANY VALUATION & FINANCIAL METRICS
 
 
 
 
 
 
 
21.9.1
COMPANY VALUATION & FINANCIAL METRICS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES PLAYERS
 
 
 
 
 
 
21.9.2
COMPANY VALUATION & FINANCIAL METRICS FOR OLIGONUCLEOTIDE-BASE DRUGS PLAYERS
 
 
 
 
 
21.10
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
21.10.1
PRODUCT APPROVALS
 
 
 
 
 
 
21.10.2
DEALS
 
 
 
 
 
 
21.10.3
EXPANSIONS
 
 
 
 
22
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
600
 
22.1
OLIGONUCLEOTIDE-BASED DRUG COMPANIES
 
 
 
 
 
 
 
22.1.1
ALNYLAM PHARMACEUTICALS, INC.
 
 
 
 
 
 
 
22.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
22.1.1.2
PRODUCTS OFFERED
 
 
 
 
 
 
22.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
22.1.1.3.1
PRODUCT APPROVALS
 
 
 
 
 
 
22.1.1.3.2
DEALS
 
 
 
 
 
 
22.1.1.3.3
EXPANSIONS
 
 
 
 
22.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
22.1.1.4.1
KEY STRENGTHS
 
 
 
 
 
 
22.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
22.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
 
 
 
22.1.2
BIOGEN INC.
 
 
 
 
 
 
22.1.3
NOVARTIS AG
 
 
 
 
 
 
22.1.4
SAREPTA THERAPEUTICS, INC.
 
 
 
 
 
 
22.1.5
ASTELLAS PHARMA INC.
 
 
 
 
 
 
22.1.6
ASTRAZENECA
 
 
 
 
 
 
22.1.7
JAZZ PHARMACEUTICALS PLC
 
 
 
 
 
 
22.1.8
GERON CORPORATION
 
 
 
 
 
 
22.1.9
IONIS PHARMACEUTICALS, INC.
 
 
 
 
 
 
22.1.10
NIPPON SHINYAKU, CO. LTD. (NS PHARMA, INC.)
 
 
 
 
 
 
22.1.11
NOVO NORDISK A/S
 
 
 
 
 
 
22.1.12
ARROWHEAD PHARMACEUTICALS, INC.
 
 
 
 
 
 
22.1.13
SANOFI
 
 
 
 
 
22.2
OLIGONUCLEOTIDE SYNTHESIS & SYNTHESIZED OLIGONUCLEOTIDE COMPANIES
 
 
 
 
 
 
 
22.2.1
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
 
 
22.2.2
MERCK KGAA
 
 
 
 
 
 
22.2.3
DANAHER CORPORATION
 
 
 
 
 
 
22.2.4
EUROFINS SCIENTIFIC
 
 
 
 
 
 
22.2.5
AGILENT TECHNOLOGIES, INC.
 
 
 
 
 
 
22.2.6
LGC LIMITED
 
 
 
 
 
 
22.2.7
TWIST BIOSCIENCE
 
 
 
 
 
 
22.2.8
GENSCRIPT
 
 
 
 
 
 
22.2.9
MARAVAI LIFESCIENCES
 
 
 
 
 
 
22.2.10
KANEKA CORPORATION
 
 
 
 
 
 
22.2.11
AZENTA US INC.
 
 
 
 
 
 
22.2.12
OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
 
 
 
 
 
 
22.2.13
BIOLEGIO B.V.
 
 
 
 
 
 
22.2.14
BIOLYTIC LAB PERFORMANCE, INC.
 
 
 
 
 
 
22.2.15
REVVITY (THROUGH SUBSIDIARY HORIZON DISCOVERY LTD.)
 
 
 
 
 
 
22.2.16
BIO-SYNTHESIS, INC.
 
 
 
 
 
 
22.2.17
CREATIVE BIOGENE
 
 
 
 
 
 
22.2.18
REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE)
 
 
 
 
 
 
22.2.19
BIOCOMMA LIMITED
 
 
 
 
23
RESEARCH METHODOLOGY
 
 
 
 
 
716
 
23.1
RESEARCH DATA
 
 
 
 
 
 
 
23.1.1
SECONDARY DATA
 
 
 
 
 
 
 
23.1.1.1
KEY SECONDARY SOURCES
 
 
 
 
 
 
23.1.1.2
KEY DATA FROM SECONDARY RESEARCH
 
 
 
 
 
23.1.2
PRIMARY DATA
 
 
 
 
 
 
 
23.1.2.1
KEY PRIMARY PARTICIPANTS
 
 
 
 
 
 
23.1.2.2
BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
 
 
23.1.2.3
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
23.2
MARKET SIZE ESTIMATION
 
 
 
 
 
 
 
23.2.1
GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET ESTIMATION, 2025
 
 
 
 
 
 
 
 
APPROACH 1: COMPANY REVENUE ANALYSIS-BASED ESTIMATION
 
 
 
 
 
 
23.2.1.2
APPROACH 2: SECONDARY RESEARCH
 
 
 
 
 
 
23.2.1.3
APPROACH 3: PRIMARY RESEARCH
 
 
 
 
 
 
23.2.1.4
KEY INDUSTRY INSIGHTS
 
 
 
 
 
 
23.2.1.5
APPROACH 3: MNM REPOSITORY ANALYSIS
 
 
 
 
 
23.2.2
SEGMENTAL MARKET SIZE ESTIMATION, 2025
 
 
 
 
 
23.3
MARKET GROWTH RATE PROJECTIONS
 
 
 
 
 
 
23.4
DATA TRIANGULATION
 
 
 
 
 
 
23.5
RESEARCH ASSUMPTIONS
 
 
 
 
 
 
23.6
RESEARCH LIMITATIONS & RISK ASSESSMENT
 
 
 
 
 
24
APPENDIX
 
 
 
 
 
732
 
24.1
DISCUSSION GUIDE
 
 
 
 
 
 
24.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
24.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
24.4
RELATED REPORTS
 
 
 
 
 
 
24.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
OLIGONUCLEOTIDE SYNTHESIS MARKET: INCLUSIONS & EXCLUSIONS
 
 
 
 
 
 
TABLE 2
OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
 
 
 
 
 
 
TABLE 3
OLIGONUCLEOTIDE-BASED DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 4
SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 5
OLIGONUCLEOTIDE SYNTHESIS MARKET: ROLE IN ECOSYSTEM
 
 
 
 
 
 
TABLE 6
AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGOS, BY KEY PLAYER, 2023–2025
 
 
 
 
 
 
TABLE 7
AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYER, 2023–2025
 
 
 
 
 
 
TABLE 8
AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIZERS, BY REGION, 2025
 
 
 
 
 
 
TABLE 9
OLIGONUCLEOTIDE SYNTHESIS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
TABLE 10
US-ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
 
 
TABLE 11
CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE SYNTHESIS MARKETCASE STUDIES OF AI IMPLEMENTATION IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET
 
 
 
 
 
 
TABLE 12
CLIENT’S READINESS TO ADOPT GENERATIVE AI IN OLIGONUCLEOTIDE SYNTHESIS MARKET
 
 
 
 
 
 
TABLE 13
OLIGONUCLEOTIDE SYNTHESIS MARKET: INDICATIVE LIST OF PATENTS, 2025
 
 
 
 
 
 
TABLE 14
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 15
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 16
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 17
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 18
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 19
REIMBURSEMENT SCENARIO FOR MAJOR COMMERCIAL OLIGONUCLEOTIDE THERAPEUTICS
 
 
 
 
 
 
TABLE 20
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%)
 
 
 
 
 
 
TABLE 21
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
 
TABLE 22
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 23
OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 24
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 25
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 26
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 27
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 28
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 29
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 30
OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY PRODUCT, 2024–2031 (VIALS/PREFILLED SYRINGES)
 
 
 
 
 
 
TABLE 31
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 32
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 33
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 34
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 35
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 36
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 37
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 38
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 39
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 40
EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 41
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 42
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 43
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 44
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 45
OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 46
APPROVED ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS
 
 
 
 
 
 
TABLE 47
ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 48
NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 49
EUROPE: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 50
ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 51
LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 52
MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 53
GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 54
APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS
 
 
 
 
 
 
TABLE 55
SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 56
NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 57
EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 58
ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 59
LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 60
MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 61
GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 62
OTHER APPROVED OLIGONUCLEOTIDE-BASED DRUGS
 
 
 
 
 
 
TABLE 63
OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 64
NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 65
EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 66
ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 67
LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 68
MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 69
GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 70
OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 71
OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 72
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 73
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 74
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 75
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 76
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 77
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 78
OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 79
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 80
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 81
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 82
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 83
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 84
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 85
OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 86
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 87
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 88
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 89
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 90
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 91
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 92
OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 93
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 94
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 95
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 96
OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 97
OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 98
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 99
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 100
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 101
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 102
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 103
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 104
OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 105
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 106
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 107
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 108
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 109
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 110
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 111
OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 112
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 113
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 114
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 115
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 116
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 117
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 118
OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 119
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 120
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 121
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 122
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 123
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 124
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 125
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 126
PRIMERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 127
NORTH AMERICA: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 128
EUROPE: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 129
ASIA PACIFIC: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 130
LATIN AMERICA: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 131
MIDDLE EAST: PRIMERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 132
GCC COUNTRIES: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 133
PROBES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 134
NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 135
EUROPE: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 136
ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 137
LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 138
MIDDLE EAST: PROBES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 139
GCC COUNTRIES: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 140
DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 141
NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 142
EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 143
ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 144
LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 145
MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 146
GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 147
RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 148
NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 149
EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 150
ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 151
LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 152
MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 153
GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 154
OTHER OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 155
NORTH AMERICA: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 156
EUROPE: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 157
ASIA PACIFIC: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 158
LATIN AMERICA: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 159
MIDDLE EAST: OTHER OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 160
GCC COUNTRIES: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 161
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 162
CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 163
NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 164
EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 165
ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 166
LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 167
MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 168
GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 169
PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 170
NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 171
EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 172
ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 173
LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 174
MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 175
GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 176
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 177
SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 178
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 179
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 180
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 181
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 182
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 183
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 184
SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 185
SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 186
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 187
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 188
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 189
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 190
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 191
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 192
SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 193
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 194
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 195
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 196
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 197
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 198
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 199
SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 200
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 201
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 202
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 203
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 204
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 205
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 206
SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAEPUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 207
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAEPUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 208
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 209
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 210
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 211
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 212
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 213
SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 214
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 215
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 216
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 217
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 218
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 219
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 220
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 221
SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 222
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 223
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 224
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 225
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 226
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 227
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 228
SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 229
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 230
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 231
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 232
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 233
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 234
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 235
SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 236
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 237
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 238
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 239
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 240
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 241
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 242
SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 243
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 244
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 245
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 246
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 247
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 248
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 249
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 250
OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 251
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 252
EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 253
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 254
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 255
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 256
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 257
OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 258
OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 259
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 260
EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 261
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 262
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 263
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 264
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 265
OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 266
PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 267
NORTH AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 268
EUROPE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 269
ASIA PACIFIC: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 270
LATIN AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 271
MIDDLE EAST: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 272
GCC COUNTRIES: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 273
PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 274
DNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 275
NORTH AMERICA: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 276
EUROPE: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 277
ASIA PACIFIC: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 278
LATIN AMERICA: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 279
MIDDLE EAST: DNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 280
GCC COUNTRIES: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 281
RNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 282
NORTH AMERICA: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 283
EUROPE: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 284
ASIA PACIFIC: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 285
LATIN AMERICA: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 286
MIDDLE EAST: RNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 287
GCC COUNTRIES: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 288
MODIFIED PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 289
NORTH AMERICA: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 290
EUROPE: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 291
ASIA PACIFIC: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 292
LATIN AMERICA: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 293
MIDDLE EAST: MODIFIED PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 294
GCC COUNTRIES: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 295
ACTIVATORS/COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 296
NORTH AMERICA: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 297
EUROPE: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 298
ASIA PACIFIC: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 299
LATIN AMERICA: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 300
MIDDLE EAST: ACTIVATORS/COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 301
GCC COUNTRIES: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 302
DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 303
NORTH AMERICA: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 304
EUROPE: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 305
ASIA PACIFIC: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 306
LATIN AMERICA: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 307
MIDDLE EAST: DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 308
GCC COUNTRIES: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 309
CAPPING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 310
NORTH AMERICA: CAPPING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 311
EUROPE: CAPPING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 312
ASIA PACIFIC: CAPPING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 313
LATIN AMERICA: CAPPING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 314
MIDDLE EAST: CAPPING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 315
GCC COUNTRIES: CAPPING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 316
OTHER REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 317
NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 318
EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 319
ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 320
LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 321
MIDDLE EAST: OTHER REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 322
GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 323
SOLID SUPPORTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 324
NORTH AMERICA: SOLID SUPPORTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 325
EUROPE: SOLID SUPPORTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 326
ASIA PACIFIC: SOLID SUPPORTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 327
LATIN AMERICA: SOLID SUPPORTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 328
MIDDLE EAST: SOLID SUPPORTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 329
GCC COUNTRIES: SOLID SUPPORTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 330
OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 331
NORTH AMERICA: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 332
EUROPE: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 333
ASIA PACIFIC: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 334
LATIN AMERICA: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 335
MIDDLE EAST: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 336
GCC COUNTRIES: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 337
OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 338
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 339
EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 340
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 341
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 342
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 343
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 344
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 345
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 346
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 347
EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 348
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 349
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 350
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 351
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 352
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 353
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 354
EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 355
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 356
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 357
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 358
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 359
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 360
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 361
EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 362
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 363
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 364
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 365
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 366
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 367
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 368
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 369
EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 370
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 371
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 372
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 373
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 374
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 375
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 376
EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 377
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 378
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 379
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 380
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 381
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 382
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 383
EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 384
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 385
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 386
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 387
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 388
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 389
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 390
EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 391
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 392
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 393
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 394
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 395
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 396
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 397
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 398
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 399
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 400
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 401
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 402
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 403
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 404
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 405
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 406
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 407
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 408
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 409
NORTH AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 410
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 411
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 412
US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 413
US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 414
US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 415
US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 416
US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 417
US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 418
US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 419
US: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 420
US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 421
US: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 422
US: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 423
US: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 424
US: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 425
US: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 426
US: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 427
CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 428
CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 429
CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 430
CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 431
CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 432
CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 433
CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 434
CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 435
CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 436
CANADA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 437
CANADA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 438
CANADA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 439
CANADA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 440
CANADA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 441
CANADA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 442
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 443
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 444
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 445
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 446
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 447
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 448
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 449
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 450
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 451
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 452
EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 453
EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 454
EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 455
EUROPE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 456
EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 457
EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 458
GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 459
GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 460
GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 461
GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 462
GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 463
GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 464
GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 465
GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 466
GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 467
GERMANY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 468
GERMANY: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 469
GERMANY: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 470
GERMANY: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 471
GERMANY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 472
GERMANY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 473
UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 474
UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 475
UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 476
UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 477
UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 478
UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 479
UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 480
UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 481
UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 482
UK: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 483
UK: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 484
UK: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 485
UK: PHOSPHORAMIDITE BUILDING BLOCKSMARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 486
UK: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 487
UK: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 488
FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 489
FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 490
FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 491
FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 492
FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 493
FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 494
FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 495
FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 496
FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 497
FRANCE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 498
FRANCE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 499
FRANCE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 500
FRANCE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 501
FRANCE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 502
FRANCE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 503
ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 504
ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 505
ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 506
ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 507
ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 508
ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 509
ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 510
ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 511
ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 512
ITALY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 513
ITALY: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 514
ITALY: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 515
ITALY: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY PHTYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 516
ITALY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 517
ITALY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 518
SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 519
SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 520
SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 521
SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 522
SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 523
SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 524
SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 525
SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 526
SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 527
SPAIN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 528
SPAIN: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 529
SPAIN: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 530
SPAIN: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 531
SPAIN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 532
SPAIN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 533
REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 534
REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 535
REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 536
REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 537
REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 538
REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 539
REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 540
REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 541
REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 542
REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 543
REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 544
REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 545
REST OF EUROPE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 546
REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 547
REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 548
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 549
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 550
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 551
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 552
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 553
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 554
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 555
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 556
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 557
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 558
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 559
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 560
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 561
ASIA PACIFIC: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 562
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 563
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 564
JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 565
JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 566
JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 567
JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 568
JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 569
JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 570
JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 571
JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 572
JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 573
JAPAN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 574
JAPAN: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 575
JAPAN: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 576
JAPAN: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 577
JAPAN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 578
JAPAN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 579
CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 580
CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 581
CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 582
CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 583
CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 584
CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 585
CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 586
CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 587
CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 588
CHINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 589
CHINA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 590
CHINA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 591
CHINA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY PHOTYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 592
CHINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 593
CHINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 594
INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 595
INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 596
INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 597
INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 598
INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 599
INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 600
INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 601
INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 602
INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 603
INDIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 604
INDIA: OLIGONUCLEOTIDE REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 605
INDIA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 606
INDIA: PHOSPHORAMIDITE BUILDING BLOCKSMARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 607
INDIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 608
INDIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 609
SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 610
SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 611
SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 612
SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 613
SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 614
SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 615
SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 616
SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 617
SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 618
SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 619
SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 620
SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 621
SOUTH KOREA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 622
SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 623
SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 624
AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 625
AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 626
AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 627
AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 628
AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 629
AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 630
AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 631
AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 632
AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 633
AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 634
AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 635
AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 636
AUSTRALIA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 637
AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 638
AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 639
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 640
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 641
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 642
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 643
REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 644
REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 645
REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 646
REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 647
REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 648
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 649
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 650
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 651
REST OF ASIA PACIFIC: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 652
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 653
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 654
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 655
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 656
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 657
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 658
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 659
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 660
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 661
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 662
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 663
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 664
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 665
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 666
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 667
LATIN AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 668
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 669
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 670
BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 671
BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 672
BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 673
BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 674
BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 675
BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 676
BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 677
BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 678
BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 679
BRAZIL: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 680
BRAZIL: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 681
BRAZIL: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 682
BRAZIL: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 683
BRAZIL: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 684
BRAZIL: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 685
MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 686
MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 687
MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 688
MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 689
MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 690
MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 691
MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 692
MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 693
MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 694
MEXICO: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 695
MEXICO: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 696
MEXICO: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 697
MEXICO: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 698
MEXICO: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 699
MEXICO: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 700
ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 701
ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 702
ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 703
ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 704
ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 705
ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 706
ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 707
ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 708
ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 709
ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 710
ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 711
ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 712
ARGENTINA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 713
ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 714
ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 715
REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 716
REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 717
REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 718
REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 719
REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 720
REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 721
REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 722
REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 723
REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 724
REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 725
REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 726
REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 727
REST OF LATIN AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 728
REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 729
REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 730
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 731
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 732
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 733
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 734
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 735
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 736
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 737
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 738
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 739
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 740
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 741
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 742
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 743
MIDDLE EAST: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 744
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 745
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 746
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 747
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 748
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 749
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 750
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 751
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 752
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 753
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 754
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 755
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 756
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 757
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 758
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 759
GCC COUNTRIES: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 760
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 761
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 762
SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 763
SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 764
SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 765
SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 766
SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 767
SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 768
SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 769
SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 770
SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 771
SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 772
SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 773
SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 774
SAUDI ARABIA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 775
SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 776
SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 777
UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 778
UAE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 779
UAE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 780
UAE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 781
UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 782
UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 783
UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 784
UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 785
UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 786
UAE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 787
UAE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 788
UAE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 789
UAE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 790
UAE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 791
UAE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 792
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 793
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 794
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 795
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 796
REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 797
REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 798
REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 799
REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 800
REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 801
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 802
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 803
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 804
REST OF GCC COUNTRIES: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 805
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 806
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 807
REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 808
REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 809
REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 810
REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 811
REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 812
REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 813
REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 814
REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 815
REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 816
REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 817
REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 818
REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 819
REST OF MIDDLE EAST: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 820
REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 821
REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 822
AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 823
AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 824
AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 825
AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 826
AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 827
AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 828
AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 829
AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 830
AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 831
AFRICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 832
AFRICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 833
AFRICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 834
AFRICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 835
AFRICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 836
AFRICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 837
KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2023–2026
 
 
 
 
 
 
TABLE 838
KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2023–2026
 
 
 
 
 
 
TABLE 839
OLIGONUCLEOTIDE-BASED DRUGS MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 840
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 841
OLIGONUCLEOTIDE-BASED DRUGS MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 842
OLIGONUCLEOTIDE-BASED DRUGS MARKET: DRUG TYPE FOOTPRINT
 
 
 
 
 
 
TABLE 843
OLIGONUCLEOTIDE-BASED DRUGS MARKET: THERAPEUTIC AREA FOOTPRINT
 
 
 
 
 
 
TABLE 844
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 845
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES: BY PRODUCT TYPE FOOTPRINTS
 
 
 
 
 
 
TABLE 846
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 847
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
 
 
 
 
 
 
TABLE 848
OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT APPROVALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 849
OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 850
OLIGONUCLEOTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2022–MAY 2025
 
 
 
 
 
 
TABLE 851
ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 852
ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 853
ALNYLAM PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 854
ALNYLAM PHARMACEUTICALS, INC.: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 855
ALNYLAM PHARMACEUTICALS, INC.: EXPANSIONS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 856
BIOGEN INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 857
BIOGEN INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 858
BIOGEN INC.: PRODUCT APPROVALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 859
BIOGEN INC.: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 860
BIOGEN INC.: EXPANSIONS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 861
NOVARTIS AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 862
NOVARTIS AG: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 863
NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 864
NOVARTIS AG: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 865
SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 866
SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 867
SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 868
SAREPTA THERAPEUTICS, INC.: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 869
SAREPTA THERAPEUTICS: EXPANSIONS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 870
ASTELLAS PHARMA INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 871
ASTELLAS PHARMA INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 872
ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 873
ASTELLAS PHARMA INC.: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 874
ASTRAZENECA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 875
ASTRAZENECA: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 876
ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 877
ASTRAZENECA: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 878
JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 879
JAZZ PHARMACEUTICALS PLC: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 880
GERON CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 881
GERON CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 882
GERON CORPORATION: PRODUCT APPROVALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 883
GERON CORPORATION: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 884
IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 885
IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 886
IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 887
IONIS PHARMACEUTICALS, INC.: DEALS, JANUARY 2023−JULY 202
 
 
 
 
 
 
TABLE 888
IONIS PHARMACEUTICALS, INC.: EXPANSIONS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 889
NIPPON SHINYAKU, CO. LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 890
NIPPON SHINYAKU, CO., LTD.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 891
NIPPON SHINYAKU, CO., LTD.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 892
NOVO NORDISK A/S: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 893
NOVO NORDISK A/S: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 894
NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 895
ARROWHEAD PHARMACEUTICALS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 896
ARROWHEAD PHARMACEUTICALS, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 897
ARROWHEAD PHARMACEUTICALS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 898
ARROWHEAD PHARMACEUTICALS, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 899
SANOFI: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 900
SANOFI: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 901
SANOFI: PRODUCT APPROVALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 902
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 903
THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 904
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 905
MERCK KGAA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 906
MERCK KGAA: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 907
MERCK KGAA: EXPANSIONS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 908
DANAHER CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 909
DANAHER CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 910
DANAHER CORPORATION: SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 911
DANAHER CORPORATION: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 912
DANAHER CORPORATION: EXPANSIONS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 913
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 914
EUROFINS SCIENTIFIC: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 915
EUROFINS SCIENTIFIC: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 916
EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 917
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 918
AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 919
AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 920
AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 921
LGC LIMITED: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 922
LGC LIMITED: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 923
LGC LIMITED: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 924
TWIST BIOSCIENCE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 925
TWIST BIOSCIENCE: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 926
TWIST BIOSCIENCE: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 927
TWIST BIOSCIENCE: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 928
GENSCRIPT: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 929
GENSCRIPT: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 930
GENSCRIPT: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 931
GENSCRIPT: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 932
GENSCRIPT: EXPANSIONS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 933
MARAVAI LIFESCIENCES: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 934
MARAVAI LIFESCIENCES: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 935
MARAVAI LIFESCIENCES: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 936
MARAVAI LIFESCIENCES: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 937
MARAVAI LIFESCIENCES: EXPANSIONS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 938
KANEKA CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 939
KANEKA CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 940
KANEKA CORPORATION: EXPANSIONS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 941
AZENTA US INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 942
AZENTA US INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 943
AZENTA US INC.: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 944
AZENTA US INC.: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 945
OLIGOMAKER APS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 946
OLIGOMAKER APS: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 947
BIOLEGIO B.V.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 948
BIOLEGIO B.V.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 949
BIOLYTIC LAB PERFORMANCE, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 950
BIOLYTIC LAB PERFORMANCE, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 951
BIOLYTIC LAB PERFORMANCE, INC.: SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 952
REVVITY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 953
REVVITY: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 954
REVVITY: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 955
BIO-SYNTHESIS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 956
BIO-SYNTHESIS, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 957
CREATIVE BIOGENE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 958
CREATIVE BIOGENE: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 959
REPROCELL INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 960
REPROCELL INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 961
BIOCOMMA LIMITED: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 962
BIOCOMMA LIMITED: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 963
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
 
 
 
 
 
 
TABLE 964
RISK ASSESSMENT
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION & REGIONS CONSIDERED
 
 
 
 
 
 
FIGURE 2
REGIONS CONSIDERED
 
 
 
 
 
 
FIGURE 3
OLIGONUCLEOTIDE SYNTHESIS MARKET: YEARS CONSIDERED
 
 
 
 
 
 
FIGURE 4
MARKET SCENARIO
 
 
 
 
 
 
FIGURE 5
GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, 2024–2031
 
 
 
 
 
 
FIGURE 6
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2023–2026
 
 
 
 
 
 
FIGURE 7
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2023–2026
 
 
 
 
 
 
FIGURE 8
DISRUPTIONS INFLUENCING GROWTH OF OLIGONUCLEOTIDE SYNTHESIS MARKET
 
 
 
 
 
 
FIGURE 9
HIGH-GROWTH SEGMENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET, 2026–2031
 
 
 
 
 
 
FIGURE 10
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN OLIGONUCLEOTIDE SYNTHESIS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 11
RISING COMMERCIALIZATION AND REGULATORY APPROVALS OF OLIGONUCLEOTIDE THERAPEUTICS TO PROPEL MARKET GROWTH
 
 
 
 
 
 
FIGURE 12
US AND OLIGONUCLEOTIDE-BASED DRUGS SEGMENT COMMANDED LARGEST MARKET SHARES IN 2025
 
 
 
 
 
 
FIGURE 13
MEXICO TO REGISTER HIGHER CAGR DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 14
OLIGONUCLEOTIDE-BASED DRUGS TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 15
OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 16
OLIGONUCLEOTIDE-BASED DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 17
SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 18
OLIGONUCLEOTIDE SYNTHESIS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 19
OLIGONUCLEOTIDE SYNTHESIS MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 20
OLIGONUCLEOTIDE-BASED DRUGS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
FIGURE 21
SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
FIGURE 22
VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
 
 
 
 
 
 
FIGURE 23
IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
 
 
 
 
 
 
FIGURE 24
TOP APPLICANTS/OWNER (COMPANIES) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS, 2015–2025
 
 
 
 
 
 
FIGURE 25
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE
 
 
 
 
 
 
FIGURE 26
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
 
FIGURE 27
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 28
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 29
REVENUE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2021–2025
 
 
 
 
 
 
FIGURE 30
REVENUE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2021–2025
 
 
 
 
 
 
FIGURE 31
OLIGONUCLEOTIDE-BASED DRUGS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2025
 
 
 
 
 
 
FIGURE 32
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2025
 
 
 
 
 
 
FIGURE 33
OLIGONUCLEOTIDE-BASED DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
 
 
 
 
 
 
FIGURE 34
OLIGONUCLEOTIDE-BASED DRUGS MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 35
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
 
 
 
 
 
 
FIGURE 36
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 37
OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
 
 
 
 
 
 
FIGURE 38
OLIGONUCLEOTIDE-BASED DRUGS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
 
 
 
 
 
 
FIGURE 39
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
 
 
 
 
 
 
FIGURE 40
EV/EBITDA OF KEY VENDORS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET
 
 
 
 
 
 
FIGURE 41
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET
 
 
 
 
 
 
FIGURE 42
EV/EBITDA OF KEY VENDORS IN OLIGONUCLEOTIDE-BASED DRUGS MARKET
 
 
 
 
 
 
FIGURE 43
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS IN OLIGONUCLEOTIDE-BASED DRUGS MARKET
 
 
 
 
 
 
FIGURE 44
ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 45
BIOGEN INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 46
NOVARTIS AG: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 47
SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 48
ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 49
ASTRAZENECA: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 50
JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 51
GERON CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 52
IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 53
NIPPON SHINYAKU, CO. LTD.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 54
NOVO NORDISK A/S: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 55
ARROWHEAD PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 56
SANOFI: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 57
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 58
MERCK KGAA: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 59
DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 60
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 61
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 62
LGC LIMITED: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 63
TWIST BIOSCIENCE: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 64
GENSCRIPT: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 65
MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 66
KANEKA CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 67
AZENTA US INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 68
REVVITY: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 69
REPROCELL INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 70
OLIGONUCLEOTIDE SYNTHESIS MARKET: RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 71
OLIGONUCLEOTIDE SYNTHESIS MARKET: BREAKDOWN OF PRIMARIES
 
 
 
 
 
 
FIGURE 72
GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET ESTIMATION, 2025
 
 
 
 
 
 
FIGURE 73
OLIGONUCLEOTIDE-BASED DRUGS MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025)
 
 
 
 
 
 
FIGURE 74
SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025)
 
 
 
 
 
 
FIGURE 75
OLIGONUCLEOTIDE SYNTHESIS MARKET: INSIGHTS FROM PRIMARIES
 
 
 
 
 
 
FIGURE 76
SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 77
OLIGONUCLEOTIDE-BASED DRUGS MARKET: CAGR PROJECTIONS
 
 
 
 
 
 
FIGURE 78
OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGOS MARKET: CAGR PROJECTIONS
 
 
 
 
 
 
FIGURE 79
OLIGONUCLEOTIDE SYNTHESIS MARKET: DATA TRIANGULATION
 
 
 
 
 
 

Methodology

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global oligonucleotide synthesis market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used primarily to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, the World Health Organization (WHO), the United States Food and Drug Administration (US FDA), the National Center for Biotechnology Information (NCBI), and regulatory body websites, among others. These sources also provided key information on major players, market classification and segmentation aligned with industry trends, regional and country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information. The following is a breakdown of the primary respondents:

Oligonucleotide Synthesis Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the oligonucleotide synthesis market. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

Oligonucleotide Synthesis Market : Top-Down and Bottom-Up Approach

Oligonucleotide Synthesis Market Top Down and Bottom Up Approach

Data Triangulation

After determining the overall market size through the estimation process, the total market was segmented into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

Market Definition

Oligonucleotide synthesis is the chemical process of creating nucleic acid fragments with specific chemical structures or sequences, of varying sizes, to form a desired product. These fragments, known as oligonucleotides, have several applications in medical and life science research. They can be used for DNA sequencing and amplification, detecting complementary DNA or RNA through hybridization, creating artificial genes, and introducing targeted genetic mutations.

Oligonucleotides are also used to develop therapeutic drugs. These drugs are chemically synthesized and have different mechanisms of action, such as interfering with gene expression, blocking the production of harmful proteins, or restoring the function of mutated genes.

Key Stakeholders

  • Pharmaceutical & biotechnology companies
  • Hospitals
  • Diagnostic laboratories
  • Academic researchers and government research organizations
  • Private research institutes
  • Custom oligonucleotide service providers
  • Contract manufacturing organizations (CMOs)
  • Oligonucleotide equipment manufacturers
  • Contract research organizations (CROs)
  • Market research & consulting firms
  • Venture capitalists

Report Objectives

  • To define, describe, and forecast the global oligonucleotide synthesis market based on the offering, type, application, end user, therapeutic area, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oligonucleotide synthesis market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the oligonucleotide synthesis market
  • To provide information on funding & investment activities, brand/product comparative analysis, vendor valuation, and financial metrics of the oligonucleotide synthesis market

Available customizations:

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

Portfolio Assessment

  • Product Matrix gives a detailed comparison of the product portfolios of the top five companies.

Geographical Analysis

  • A further breakdown of the Rest of Europe’s oligonucleotide synthesis market into countries
  • A further breakdown of the Rest of Asia Pacific’s oligonucleotide synthesis market into countries
  • A further breakdown of the Rest of Latin America’s oligonucleotide synthesis market into countries
  • A further breakdown of the Rest of Middle East’s oligonucleotide synthesis market into countries

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

 

Table of Contents

Methodology

 Request Customization Speak to Analyst
Speak to Analyst
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Synthesis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Oligonucleotide Synthesis Market

avtar

Adam

Jul, 2026

I reviewed the Oligonucleotide Synthesis Market insights to better understand how custom synthesis demand is evolving across therapeutic development and large-scale genomic research programs..

avtar

Douglas

Jul, 2026

From a strategic planning perspective, the Oligonucleotide Synthesis Market analysis helped me evaluate how manufacturing scalability and regulatory expectations could influence long-term supplier partnerships..

avtar

Nathan

Jul, 2026

I found the breakdown of applications and technology adoption in the Oligonucleotide Synthesis Market particularly useful for assessing future investment opportunities in precision medicine and RNA-based therapeutics..

bottom banner
DMCA.com Protection Status
popup img